Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Martedì 14 marzo 2023
circa 1 minuti di lettura
Journal and Affiliations:
Annals of Oncology, 14 marzo 2023
Silke Gillessen Sommer, Istituto Oncologico della Svizzera italiana, EOC, Lugano
Tags:
abiraterone–prednisone
cabazitaxel
clinical practice guideline
darolutamide
Lu-PSMA
prostate cancer
Authors:
Silke Gillessen Sommer